Last reviewed · How we verify

vaccination PNEUMOVAX 23 — Competitive Intelligence Brief

vaccination PNEUMOVAX 23 (vaccination PNEUMOVAX 23) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polysaccharide vaccine. Area: Immunology / Infectious Disease.

phase 3 Polysaccharide vaccine Streptococcus pneumoniae capsular polysaccharides (23 serotypes) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

vaccination PNEUMOVAX 23 (vaccination PNEUMOVAX 23) — Walvax Biotechnology Co., Ltd.. PNEUMOVAX 23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
vaccination PNEUMOVAX 23 TARGET vaccination PNEUMOVAX 23 Walvax Biotechnology Co., Ltd. phase 3 Polysaccharide vaccine Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
Meningococcal A (control) Meningococcal A (control) International Vaccine Institute marketed polysaccharide vaccine Neisseria meningitidis serogroup A capsular polysaccharide
ProDiax-23 (PPSV23) ProDiax-23 (PPSV23) Korea University Guro Hospital marketed Polysaccharide vaccine Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
Investigational 23-valent PPV Investigational 23-valent PPV Sinovac Biotech Co., Ltd marketed Pneumococcal polysaccharide vaccine Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
PPV Vaccine PPV Vaccine Fakultas Kedokteran Universitas Indonesia marketed Polysaccharide vaccine Streptococcus pneumoniae capsular polysaccharides
Typhoid Vi vaccine Typhoid Vi vaccine International Vaccine Institute marketed polysaccharide vaccine Salmonella typhi Vi polysaccharide capsular antigen
Pneumovax™23 Pneumovax™23 Merck Sharp & Dohme LLC marketed Polysaccharide vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polysaccharide vaccine class)

  1. Korea University Guro Hospital · 2 drugs in this class
  2. Celgene · 1 drug in this class
  3. Fakultas Kedokteran Universitas Indonesia · 1 drug in this class
  4. Hoffmann-La Roche · 1 drug in this class
  5. Hualan Biological Engineering, Inc. · 1 drug in this class
  6. Merck Sharp & Dohme LLC · 1 drug in this class
  7. University Hospital, Montpellier · 1 drug in this class
  8. University of Minnesota · 1 drug in this class
  9. Astellas Pharma Inc · 1 drug in this class
  10. Walvax Biotechnology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). vaccination PNEUMOVAX 23 — Competitive Intelligence Brief. https://druglandscape.com/ci/vaccination-pneumovax-23. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: